Hepatotoxicity of Nonsteroidal Anti-Inflammatory Drugs: A Systematic Review of Randomized Controlled Trials

Table 3

Outcome of studies indicating hepatotoxicity in this systematic review.

Number	Study	Intervention (dose/day)	Number of patients included	Hepatotoxic outcome; Number of events (percentage of events)
				AST > 3 ULN	ALT > 3 ULN	ALT, AST, or both > 3 ULN	ALP > 2 ULN	Hy’s cases	Liver-related discontinuation	Liver-related hospitalization
1	Buxton et al. 1978 [16]	Fenbufen 600 mg	20	2 (10.0)			3 (15.0)
5	Kennedy et al. 1994 [20]	Diclofenac 150 mg	121			14 (12.0); 5 (4.1)
8	McKenna et al. 2001 [23]	Diclofenac 150 mg	199	2 (1.0)	5 (2.5)
10	Tugwell et al. 2004 [25]	Diclofenac 150 mg	311	4 (1.4)	13 (4.7)
		Topical diclofenac 1.5% w/w 1.55 ml	311	1 (0.4)	3 (1.1)
12	Laine et al. 2009 [27]	Diclofenac 150 mg	17289	246 (1.4); 104 (0.6); 31 (0.2)	511 (3.0); 228 (1.3); 83 (0.5)			2 (0.012)	461 (2.7)	4 (0.023)
		Etoricoxib 60 mg or 90 mg	17412			116 (0.7 ); 38 (0.2); 8 (0.05)		1 (0.006)	57 (0.3)
13	Dahlberg et al. 2009 [28]	Diclofenac 100 mg	462						8 (1.7)
		Celecoxib 200 mg	463						1 (0.2)
16	Chopra et al. 2013 [31]	Celecoxib 200 mg	110		2 (1.9)
		SGCG & SCG	220		10 (4.5)				7 (3.2)
17	Altman et al. 2015 [32]	Low dose SoluMatrix diclofenac 75–105 mg	601	8 (1.4)	24 (4.1)		16 (2.7)	1 (0.2)	23 (3.8)

Remark. Hy’s cases: ALT > 3 ULN, and bilirubin ≥ 2 ULN; more than 3–6 ULN; more than 5 ULN; more than 8 ULN; more than 10 ULN; more than 1.5 ULN.